中华器官移植杂志
中華器官移植雜誌
중화기관이식잡지
CHINESE JOURNAL OF ORGAN TRANSPLANTATION
2011年
3期
172-176
,共5页
胰岛移植%间质干细胞%T淋巴细胞,辅助诱导%免疫耐受%糖尿病
胰島移植%間質榦細胞%T淋巴細胞,輔助誘導%免疫耐受%糖尿病
이도이식%간질간세포%T림파세포,보조유도%면역내수%당뇨병
Islet transplantation%Mesenchymal stem cellls%T-lymphocytes,helper-mducer%Immune tolerance%Diabetes mellitus
目的 研究同种异体或自体的大鼠骨髓间充质干细胞(MSC)与胰岛肝内联合移植对胰岛移植物的免疫调节作用及其机制.方法 以链佐星制备Lewis大鼠的糖尿病模型,作为胰岛移植受者,分为3组:单纯移植组大鼠经门静脉单独移植SD大鼠胰岛6000 IEQ/kg;同系MSC组大鼠经门静脉共同移植1×109/L的Lewis大鼠MSC 1 ml与SD大鼠胰岛6000 IEQ/kg;同种MSC组大鼠经门静脉共同移植1×109/L的SD大鼠MSC 1 ml与SD大鼠胰岛6000 IEQ/kg.检测受鼠的血糖变化,术后1、3 d大鼠外周血γ干扰素(IFN-γ)、白细胞介素(IL)-2、IL-4和IL-10的含量.结果 3组大鼠术后第1天血糖均下降到13.9 mmol/L以下.同系MSC组移植物存活时间为(11.38±4.03)d,同种MSC组为(5.50±2.07)d,单纯移植组为(2.88±1.25)d(P＜0.01).术后1、3 d,单纯移植组IFN-γ和IL-2的含量显著高于同系MSC组和同种MSC组(P＜0.01),同种MSC组IFN-γ和IL-2的含量高于同系MSC组(P＜0.05);单纯移植组IL-10的含量低于同系MSC组和同种MSC组(P＜0.01),同系MSC组IL-10的含量与司种MSC组相比较,差异无统计学意义(P＞0.05);各组IL-4含量的差异无统计学意义(P＞0.05).结论 MSC与同种胰岛共移植可以延长胰岛移植物存活时间,应用同系MSC的效果优于同种异体MSC.共移植的MSC主要通过减少TH1类细胞因子(IFN-y和IL-2)的表达使受者TH1/TH2平衡向TH2方向偏移.
目的 研究同種異體或自體的大鼠骨髓間充質榦細胞(MSC)與胰島肝內聯閤移植對胰島移植物的免疫調節作用及其機製.方法 以鏈佐星製備Lewis大鼠的糖尿病模型,作為胰島移植受者,分為3組:單純移植組大鼠經門靜脈單獨移植SD大鼠胰島6000 IEQ/kg;同繫MSC組大鼠經門靜脈共同移植1×109/L的Lewis大鼠MSC 1 ml與SD大鼠胰島6000 IEQ/kg;同種MSC組大鼠經門靜脈共同移植1×109/L的SD大鼠MSC 1 ml與SD大鼠胰島6000 IEQ/kg.檢測受鼠的血糖變化,術後1、3 d大鼠外週血γ榦擾素(IFN-γ)、白細胞介素(IL)-2、IL-4和IL-10的含量.結果 3組大鼠術後第1天血糖均下降到13.9 mmol/L以下.同繫MSC組移植物存活時間為(11.38±4.03)d,同種MSC組為(5.50±2.07)d,單純移植組為(2.88±1.25)d(P＜0.01).術後1、3 d,單純移植組IFN-γ和IL-2的含量顯著高于同繫MSC組和同種MSC組(P＜0.01),同種MSC組IFN-γ和IL-2的含量高于同繫MSC組(P＜0.05);單純移植組IL-10的含量低于同繫MSC組和同種MSC組(P＜0.01),同繫MSC組IL-10的含量與司種MSC組相比較,差異無統計學意義(P＞0.05);各組IL-4含量的差異無統計學意義(P＞0.05).結論 MSC與同種胰島共移植可以延長胰島移植物存活時間,應用同繫MSC的效果優于同種異體MSC.共移植的MSC主要通過減少TH1類細胞因子(IFN-y和IL-2)的錶達使受者TH1/TH2平衡嚮TH2方嚮偏移.
목적 연구동충이체혹자체적대서골수간충질간세포(MSC)여이도간내연합이식대이도이식물적면역조절작용급기궤제.방법 이련좌성제비Lewis대서적당뇨병모형,작위이도이식수자,분위3조:단순이식조대서경문정맥단독이식SD대서이도6000 IEQ/kg;동계MSC조대서경문정맥공동이식1×109/L적Lewis대서MSC 1 ml여SD대서이도6000 IEQ/kg;동충MSC조대서경문정맥공동이식1×109/L적SD대서MSC 1 ml여SD대서이도6000 IEQ/kg.검측수서적혈당변화,술후1、3 d대서외주혈γ간우소(IFN-γ)、백세포개소(IL)-2、IL-4화IL-10적함량.결과 3조대서술후제1천혈당균하강도13.9 mmol/L이하.동계MSC조이식물존활시간위(11.38±4.03)d,동충MSC조위(5.50±2.07)d,단순이식조위(2.88±1.25)d(P＜0.01).술후1、3 d,단순이식조IFN-γ화IL-2적함량현저고우동계MSC조화동충MSC조(P＜0.01),동충MSC조IFN-γ화IL-2적함량고우동계MSC조(P＜0.05);단순이식조IL-10적함량저우동계MSC조화동충MSC조(P＜0.01),동계MSC조IL-10적함량여사충MSC조상비교,차이무통계학의의(P＞0.05);각조IL-4함량적차이무통계학의의(P＞0.05).결론 MSC여동충이도공이식가이연장이도이식물존활시간,응용동계MSC적효과우우동충이체MSC.공이식적MSC주요통과감소TH1류세포인자(IFN-y화IL-2)적표체사수자TH1/TH2평형향TH2방향편이.
Objective To compare the immune regulation of syngenic and allogenic mesenchymal stem cells (MSCs) in the transplantation combined with islets. Methods After induction of diabetes in 30 Lewis rats with streptozotocin (STZ), the recipient Lewis rats received islets from SD rats combined with syngenic (group B) or allogenic (group C) MSCs injection via the portal vein. The group of islets transplanted alone served as control (group A). The survival time of grafts in all groups was assessed by the level of blood glucose. ELISA was used to detect the levels of interferon-γ (IFN-γ), interleukin 2 (IL-2), IL-4 and IL-10 in the peripheral blood on the 1st and 3rd day after transplantation. Results The blood glucose levels in all three groups were decreased in a normal range (13. 9 mmol/L) and the survival time of grafts in group B (11.38 ± 4. 03 days) was significantly longer than in group C (5. 50± 2. 07 days) as well as group A (2. 88 ± 1.25 days). On the 1 st and 3rd day after transplantation, the levels of TH 1 cytokines IFN-γ and IL-2 in group A were significantly higher than in groups C and B (P＜0.05). Meanwhile the levels of TH 2 cytokine IL-10were increased in group B, but there was no significant difference between groups A and C (P＞0.05). The levels of IL-4 had no significant difference among these three groups (P ＞ 0.05).Conclusion Islet transplantation combined with MSCs could prolong the survival time of grafts.Syngenic MSCs, superior to allogenic ones, were more effective in changing the balance of TH1/TH2to TH2. Decreased expression of TH1 cytokine (IFN-γ, IL-2), which was closely related to the induction of immune tolerance, was beneficial to the long-term survival of grafts.
